Hitonowa Medical

Hitonowa Medical is a Tokyo-based regenerative medicine clinic and clinical research center specializing in the treatment of intractable neurological diseases. Founded in 2020, the clinic focuses on the clinical application of stem cell-conditioned media derived from human exfoliated deciduous teeth (SHED-CM), also known as the U-Factor® solution. Its primary therapeutic focus includes Amyotrophic Lateral Sclerosis (ALS), stroke sequelae, and dementia, utilizing a combination of regenerative cytokine therapy and advanced rehabilitation technologies like VR. Hitonowa Medical works in close partnership with the biotech company U-Factor Co., Ltd. to conduct clinical trials and has received academic recognition for its research in ALS. The clinic aims to provide new therapeutic options for patients with unmet medical needs through evidence-based regenerative medicine.